Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Asthmatic Agents
/ therapeutic use
Antibodies, Monoclonal
/ administration & dosage
Antibodies, Monoclonal, Humanized
/ administration & dosage
Asthma
/ drug therapy
Child
Clinical Trials as Topic
Female
Glycosylation
/ drug effects
Histocompatibility Antigens Class I
/ metabolism
Humans
Immunoglobulin G
/ drug effects
Male
Middle Aged
Omalizumab
/ administration & dosage
Receptors, Fc
/ metabolism
Severity of Illness Index
Young Adult
Benralizumab
Dupilumab pharmacokinetics
Mepolizumab
Monoclonal antibodies
Omalizumab
Reslizumab
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
08
03
2019
revised:
05
05
2019
accepted:
09
05
2019
pubmed:
29
5
2019
medline:
22
7
2020
entrez:
29
5
2019
Statut:
ppublish
Résumé
Several monoclonal antibodies (mAbs) (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) are currently approved for the treatment of severe asthma. They have complex pharmacokinetic profiles. These profiles are unique in that they are dependent on their structure as well as can be markedly influenced by the biology of their target antigen, but their general behaviour can still be considered a class property, similar to their endogenous IgG counterpart. They cannot be administered by oral route, have a slow distribution into tissue, are metabolized to peptides and amino acids in several tissues but are protected from degradation by binding to protective receptors (the FcRn), which explains their long elimination half-lives. Their clearance is nonlinear because of the saturation of the target-mediated elimination. Also anti-drug antibody (ADA) response and off-target binding, as well as their glycosylation pattern, can influence the pharmacokinetics of mAbs.
Identifiants
pubmed: 31136930
pii: S0954-6111(19)30157-X
doi: 10.1016/j.rmed.2019.05.005
pii:
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Histocompatibility Antigens Class I
0
Immunoglobulin G
0
Receptors, Fc
0
Omalizumab
2P471X1Z11
reslizumab
35A26E427H
dupilumab
420K487FSG
benralizumab
71492GE1FX
mepolizumab
90Z2UF0E52
Fc receptor, neonatal
TW3XAW0RCY
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-13Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.